Association of Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)

Hallym University

Status: Unknown

Conditions: Acute Ischemic Stroke

Study type: Observational

Funder types: Other

Identifiers

NCT01233986

ABYSS

Details and patient eligibility

About

The purpose of this study is to evaluate whether the serum apoB48 level is associated with atherosclerotic ischemic stroke.

Enrollment: 112 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Large artery atherosclerotic ischemic stroke group(LAA group)

• Age over 20 years
• Patients with symptomatic stenosis in the eligible vessels(the middle cerebral artery, anterior cerebral artery, or internal carotid artery) as assessed by MRA or CTA corresponding to the acute ischemic stroke
• Patients without the occlusion of corresponding artery by MRA or CTA
• The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke

Small vessel occlusive ischemic stroke group (SVO group)

• Age over 20 years
• Patients with acute ischemic stroke of basal ganglia, internal capsule, or corona radiata
• Patients without both symptomatic and asymptomatic arterial occlusion or stenosis by MRA or CTA
• Patients without a history of systemic atherosclerosis(for example, acute myocardial infarction, angina, peripheral arterial disease, aortic aneurysm)
• The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke

Exclusion Criteria: both LAA group and SVO group

• Patients with cardioembolic ischemic stroke
• Patients treated with lipid lowering agents or steroid within the previous 30 dsys
• Patients with severe liver disease (AST >100 or ALT >100) at the time of randomization
• Patients with endocrine disease except diabetes mellitus at the time of randomization (for example, thyroid disease, adrenal disease)
• Patients with severe renal disease (serum creatinine >2.0mg/dl)at the time of randomization
• chronic alcoholics or drug user
• Patients with infection at the time of randomization
• Patients, in the opinion of the investigator, unlikely to comply with the clinical study or unsuitable for the any other disease or reason
• Informed consent has not been obtained

Trial design

112 participants in 2 patient groups

Case group - Large artery atherosclerosis

Control group-Small vessel occlusion